TY - JOUR AU - Giuliano, Anna AU - Pilon-Thomas, Shari AU - Schell, Michael AU - Abrahamsen, Martha AU - Islam, Jessica AU - Isaacs-Soriano, Kimberly AU - Kennedy, Kayoko AU - Dukes, Christopher AU - Whiting, Junmin AU - Rathwell, Julie AU - Hensel, Jonathan AU - Mangual, Leslie AU - Schonbrunn, Ernst AU - Bikowitz, Melissa AU - Grassie, Dylan AU - Yang, Yan T1 - SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021 T2 - Emerging Infectious Disease journal PY - 2022 VL - 28 IS - 3 SP - 556 SN - 1080-6059 AB - Estimating the actual extent of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging because virus test positivity data undercount the actual number and proportion of persons infected. SARS-CoV-2 seroprevalence is a marker of past SARS-CoV-2 infection regardless of presence or severity of symptoms and therefore is a robust biomarker of infection period prevalence. We estimated SARS-CoV-2 seroprevalence among residents of Hillsborough County, Florida, USA, to determine factors independently associated with SARS-CoV-2 antibody status overall and among asymptomatic antibody-positive persons. Among 867 participants, SARS-CoV-2 period prevalence (October 2020–March 2021) was 19.5% (asymptomatic seroprevalence was 8%). Seroprevalence was 2-fold higher than reported SARS-CoV-2 virus test positivity. Factors related to social distancing (e.g., essential worker status, not practicing social distancing, contact with a virus-positive person, and length of contact exposure time) were consistently associated with seroprevalence but did not differ by time since suspected or known infection (<6 months vs. >6 months). KW - COVID-19 KW - coronavirus disease KW - SARS-CoV-2 KW - severe acute respiratory syndrome coronavirus 2 KW - viruses KW - respiratory infections KW - zoonoses KW - vaccine-preventable diseases KW - serosurvey KW - seroprevalence KW - seroepidemiologic studies KW - Hillsborough County KW - Florida KW - United States DO - 10.3201/eid2803.211495 UR - https://wwwnc.cdc.gov/eid/article/28/3/21-1495_article ER - End of Reference